Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0650-0013 A · 1 trial · 1 indication
Measured as number of events.
| Arm | Type | Description |
|---|---|---|
| NNC0650-0013: Subcutaneous dose | EXPERIMENTAL | Participants will receive NNC0650-0013 subcutaneously in an ascending dose manner. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive matching placebo to NNC0650-0013 subcutaneously. |
| NNC0650-0013: Intravenous dose | EXPERIMENTAL | Participants will receive NNC0650-0013 in an ascending dose manner intravenously. |
| Name | Type | Description |
|---|---|---|
| NNC0650-0013 A | DRUG | NNC0650-0013 will be administered subcutaneously or intravenously. |
| Placebo | DRUG | Subcutaneous administration. |
Inclusion Criteria: * Male. * Age 18-55 years (both inclusive) at the time of signing the informed consent. * Body mass index between 24.0 and 29.9 kilogram per meter square (kg/m\^2) (both inclusive) at screening. * Considered to be otherwise healthy based on the medical history, physical examinat...
NNC0650-0013 A is an investigational small molecule medicine being developed by Novo Nordisk A/S. It has been studied in a Phase 1 research trial in healthy male participants. The specific disease or condition it is intended to treat has not been disclosed.
NNC0650-0013 A is being developed by Novo Nordisk A/S, which trades under the ticker NVO. Novo Nordisk is the sponsor of the clinical program for this investigational small molecule.
NNC0650-0013 A is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The program remains investigational and has not been approved by the FDA.
NNC0650-0013 A has been evaluated in one Phase 1 trial, NCT06284798, titled A Research Study of a New Medicine (NNC0650-0013) in Healthy Men. The trial enrolled 11 participants in Germany, was randomized, double-blind, and placebo-controlled, and is now completed.
NNC0650-0013 A is an investigational medicine with no disclosed therapeutic indication. Its only reported clinical study was conducted in healthy male volunteers rather than in patients with a specific disease, so no approved or intended use has been established.